Ca-AKG and fisetin: pairing a Krebs cycle metabolite with a senolytic

Ca-AKG and fisetin target different parts of the aging-biology story, but no human study has shown that taking them together produces a better outcome than taking either one alone.

Fisetin is a flavonoid investigated as a senotherapeutic, with foundational senolytic evidence in preclinical models and a growing human trial literature. Ca-AKG is a metabolic salt with links to TCA-cycle biology, alpha-ketoglutarate-dependent enzymes, nutrient sensing and senescence-associated signaling.

That makes the pairing mechanistically interesting. It does not make it a validated longevity protocol.

How are fisetin and Ca-AKG different?

The most useful distinction is what happens to senescent cells.

Fisetin's foundational 2018 study found selective senolytic activity in cell systems and reduced senescence burden in aged mice; late-life fisetin treatment also improved healthspan and lifespan in that mouse program [1].

Ca-AKG did something different in the 2020 Shahmirzadi study. In senescent human fibroblasts, AKG reduced several SASP inflammatory signals without clearly eliminating the senescent state itself [2].

That supports describing the Ca-AKG effect as senomorphic-like rather than senolytic.

Is fisetin proven to clear senescent cells in humans?

Not to the same degree as the mouse and cell literature would suggest.

Human fisetin research has expanded beyond pure preclinical work, including randomized clinical studies and senescence-focused trials. But the evidence is still developing, outcomes vary by population, and a supplement dose that reliably clears senescent cells across human tissues has not been established.

A completed Phase 2 skeletal-health trial enrolled older women and included CTX, P1NP, bone density and circulating SASP measures [3]. Those results should be interpreted at the arm and endpoint level rather than converted into a universal “fisetin clears senescent cells in humans” claim.

For the full evidence base, see the Fisetin Data Center.

Why do people combine fisetin and Ca-AKG?

The theoretical logic is sequential rather than redundant:

• fisetin may target some senescent cells or senescence-related pathways;
• Ca-AKG may alter SASP, metabolic and epigenetic signaling in cells that remain;
• the compounds therefore do not obviously compete for one identical target.

That is a coherent research hypothesis. It is not evidence of synergy.

Has Ca-AKG + fisetin been tested together?

We found no published human trial testing the combination as a defined intervention for biological age, frailty, inflammation, physical function or another longevity outcome.

We also do not have a combination-specific dose-response or safety study.

So a claim such as “fisetin clears the bad cells and Ca-AKG rejuvenates the good cells” is a mechanistic story, not a demonstrated clinical sequence.

Could Ca-AKG interfere with fisetin's senolytic effect?

There is no direct study answering this.

Ca-AKG has context-dependent effects on autophagy, mTOR/AMPK signaling, immune metabolism and senescence-associated pathways. Fisetin also affects multiple signaling systems beyond senolysis.

Without a combination experiment, we cannot assume the effects are simply additive—or that they are completely independent.

What about the mouse lifespan evidence?

Both compounds have positive mouse longevity stories, and both require replication context.

Fisetin extended healthspan/lifespan in the foundational 2018 mouse study [1], but later genetically heterogeneous mouse testing has not produced a universal lifespan effect.

Ca-AKG's 2020 C57BL/6 study reported female lifespan extension and lower frailty burden, while two later NIA Interventions Testing Program experiments in UM-HET3 mice did not reproduce lifespan extension [2] [4] [5].

Positive mouse findings for two ingredients do not become stronger evidence merely because the ingredients are combined.

Should fisetin be pulsed while Ca-AKG is taken daily?

There is no combination trial establishing an optimal schedule.

Some experimental and clinical fisetin protocols use intermittent or short-course dosing because the intended senotherapeutic concept differs from continuous nutrient supplementation. Ca-AKG studies more commonly use daily exposure.

That does not establish a universal consumer protocol or prove that a particular pulse schedule is optimal.

What are the safety considerations?

Each compound has its own evidence and uncertainty.

Ca-AKG contributes calcium and has medication-timing considerations related to that calcium component. See Ca-AKG side effects.

Fisetin's human evidence base is growing, but high-dose or intermittent senotherapeutic use should not be treated as equivalent to dietary fisetin exposure.

Because the combination itself has not been systematically tested, its safety cannot be inferred perfectly from each ingredient in isolation.

Does it make sense to stack them?

Mechanistically, the pairing is not irrational. Evidence-wise, it remains unvalidated.

A disciplined way to think about it is:

• decide whether the evidence for Ca-AKG independently justifies its use;
• decide whether the evidence for fisetin independently justifies its use;
• then recognize that using both creates a third, less-tested intervention: the combination.

That is different from assuming two plausible compounds automatically create a better anti-aging protocol.

Bottom line

Fisetin and Ca-AKG have genuinely different senescence-related mechanisms in experimental research. Fisetin has stronger preclinical senolytic evidence, while Ca-AKG has senomorphic-like SASP and broader metabolic/epigenetic effects.

No published human study has shown that the combination is synergistic, safer, more effective, or superior for longevity.

Evaluate the two evidence bases separately. If both are used, treat the combination as an unvalidated stack rather than a proven protocol.

For the broader stacking framework, see Ca-AKG stacking.